Logo

Paradigm Therapeutics, Genmab to Develop Antibody Tx

Apr 11, 2002

NEW YORK, April 11 - Genmab and Paradigm Therapeutics today said they plan to co-develop new antibody therapeutics.

The partners will combine Paradigm's disease targets and bioinformatics platform with Genmab's fully human antibody technology to develop therapeutics for cancer, inflammatory diseases, and other states.

Genmab and Paradigm will share development costs along with any revenue that may come from out-licensing or selling potential products. Financial details were not disclosed.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.